If your organization Press; SEC Filings; Webcasts & Presentations; Analyst Coverage; Corporate Governance and Committee Charters; For Patients; Careers. Antares Pharma Inc. (NASDAQ: ATRS) share prices have increased by 7.05% over the past week, but are up 25.09% over prices posted in the last quarter. Manufacturing Engineer II. ATRS. Please enter your email address so we can determine if you need to complete a permission form or verify that you have already completed this form. Find out all the key statistics for Antares Pharma, Inc. (ATRS), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. The institutional Ownership of the shares of 43.1 stands at 0.80%, this figure is decreased -5.7 in the last six months. The shares of Antares Pharma, Inc. (NASDAQ:ATRS) shrinked -36.57% for the yearly performance. Persisted access using your organization’s identifier stored in your user browser for 90 days. EWING, N.J., November 29, 2018 — Antares Pharma, Inc. (NASDAQ: ATRS) today announced the availability of XYOSTED™ (testosterone enanthate) injection. You have the right to opt-out of sharing your email address with your organization but doing so may negatively affect your organization’s decision to renew their subscription to AdisInsight. Adis International Ltd. Part of The EPS estimate for next year as estimated by analysts is at 0.25 while EPS for next quarter is estimated at 0.03. The trailing twelve month Revenue of Antares Pharma, Inc. (NASDAQ:ATRS) is reported at 137.6 Million with income of 5.6 Million. Find the latest Antares Pharma, Inc. (ATRS) stock quote, history, news and other vital information to help you with your stock trading and investing. A proprietary, subcutaneous once-weekly testosterone enanthate product is being developed by Antares Pharma, for the treatment of men with symptomatic View the real-time ATRS price chart on Robinhood and decide if you want to buy or sell commission-free. Please click the button to participate in our quick survey. Federated access using single sign-on credentials. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Antares Pharma, Inc. (NASDAQ:ATRS) stands at 4.2, 10.6 and 1 respectively. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. To gain full access to the content and functionality of the AdisInsight database try one of the following. If your organization Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. Privacy Policy, Disclaimer, General Terms & Conditions. The company develops needle-free systems for administering injectable drugs. The company has a market capitalization of $508.24 Million. Earnings per Share growth for this year is reported at 69.9, while the analysts estimated the EPS growth for next year at 0.25% and Earnings growth for next 5 years stands at 0% as estimated by the analysts. Antares Pharma, Inc. 27 November 2019. Our Culture and Our People; Antares Benefits; Open Positions; Contact Us Meanwhile, Antares has a number of products either through trials like ELESTRIN for menopause (partnered with Jazz) and ANTUROL for overactive bladders, or … A high-level overview of Antares Pharma, Inc. (ATRS) stock. There's no doubt that we learn most about debt from the balance sheet. Find the latest news headlines from Antares Pharma, Inc. Common Stock (ATRS) at Nasdaq.com. Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results finance.yahoo.com - November 5 at 8:09 AM: Antares Pharma (ATRS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release finance.yahoo.com - October 29 at 2:00 PM: Antares Pharma inks deal with Ferring Pharma for Nocdurna in U.S. Two analysts have rated the stock with a hold rating and four have given a buy … This position will design, develop, and implement manufacturing processes and equipment to support existing commercial products and products in development. Antares Pharma, Inc. (NASDAQ: ATRS) today announced the approval of XYOSTED™ (testosterone enanthate) injection by the U.S. Food and Drug Administration (FDA). Testosterone can be abused, when taken at higher than prescribed doses and when used with other anabolic androgenic steroids. How to enable JavaScript in your browser? Antares Pharma is a specialty pharmaceutical company which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. Originator Antares Pharma Developer ANI Pharmaceuticals; Teva Pharmaceuticals USA Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners Mechanism of Action Androgen receptor agonists; Testosterone agonists That is why AdisInsight collects the minimum amount of information necessary to enable functionality, report usage, and contact you with information about AdisInsight. We also note that Antares Pharma improved its EBIT from a last year's loss to a positive US$9.2m. Contact your organization’s admin about adding this content to your AdisInsight subscription. There have been reports of misuse of men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice. Trading at 73.2% below our estimate of its fair value. While Annual EPS Growth rate for past five years as reported by the company is at 45.9%. Interview. We would love to hear your thoughts or feedback on how we can improve your experience! By accessing or using the AdisInsight platform you agree to the terms of use. The quick ratio and the current ratio of Antares Pharma, Inc. (NASDAQ:ATRS) are reported at 2.4 and 2.9 respectively. XYOSTED™ is the only FDA approved subcutaneous testosterone product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot® auto injector. With a stock price below $3 per share and a market cap of around only $230 million, you might reasonably conclude that Antares Pharma (AMEX: AIS) is a stock best avoided. Antares Pharma Inc. ATRS 3.87 0.12 (3.01%). 7.1 Insulin. But it is future earnings, more than anything, that will determine Antares Pharma's ability to maintain a … Pat brings over 30 years of experience in the pharma/biotech industry with a proven track record of leading and growing commercial organizations across a diverse set of companies, markets and therapeutic areas. Stock analysis for Antares Pharma Inc (ATRS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Testosterone, often in combination with other anabolic androgenic steroids (AAS), and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. Antares Pharma, Inc. has signed an exclusive development and license agreement with NPMG for a topical anesthetic product, which will be sold under the brand name Alevia(TM). Antares Pharma, Inc. (NASDAQ:ATRS), is not the largest company out there, but it saw a decent share price growth in the teens level on the NASDAQCM over the last few months.With many analysts covering the stock, we may expect any price-sensitive announcements have … Changes in insulin sensitivity or glycemic control may occur in patients treated with androgens. Going further back, the stock’s price has tanked 6.71% over the last 6 months but is down -28.94% in year-to-date trading. No fluff and got straight to the point. The insider ownership for the shares of Antares Pharma, Inc. (NASDAQ:ATRS) is ticked at 2.8%, the figure is rose 0.36% in the last six months. Antares Pharma, Inc. (NASDAQ:ATRS) closed at $3.14 on the last trading session with an increase of 0.64%, whereas, it previously closed at $3.12. Antares Pharma, Inc. (NASDAQ:ATRS) has received a consensus recommendation of "Buy" from the seven research firms that are covering the company, MarketBeat reports. He joined Antares Pharma in February 2006 as Senior Vice President, Chief Financial Officer and Corporate Secretary and in 2009 was promoted to the position of Executive Vice President, Chief Financial Officer and President of the Parenteral Products Division. Antares Pharma was developing a transdermal gel product containing ethinylestradiol and norelgestromin (AP 1081) for contraception, using its proprietary Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference Read More. A link to download a PDF version of the drug profile will be included in your email receipt. The company has a market capitalization of $508.24 Million. Some important ratios are also vital to discuss the performance of the company and its shares. EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer has participated in a fireside chat presentation and will host investor meetings at the Piper Sandler 32 nd Annual Virtual Healthcare Conference being held on December 1 … This privacy policy applies to this website and all websites owned and operated by Antares Pharma, Inc. (“Antares”). -Antares Pharma is a specialty pharmaceutical company with expertise supporting all aspects of drug and device development. Partnering with Antares; Devices; For Investors. XYOSTED™ is the first FDA approved subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot® auto injector. Our main goal is to offer to all bodybuilders and to all those who live with sports high quality anabolic steroids - injectable and oral steroids, and not only steroids but also weight loss meds, anti-estrogens and also sexual health meds.. Antares Pharma has 178 employees across 2 locations and $123.86 M in annual revenue in FY 2019. The U.S. Food and Drug Administration on Monday approved Antares Pharma Inc's injectable drug to treat low testosterone levels in men, the company said, nearly a year after being rejected. Antares Pharma's stock plunges 40% premarket toward 8-mo. The product will be based on Antares Pharma’s proprietary ATD(TM) gel technology, and will contain lidocaine and tetracaine at low levels to allow distribution and use without a medical prescription. Open Position at Antares Pharma. If you opt-out your email will still be collected for registration purposes. does not have a subscription POSITION SUMMARY . Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and … You need to be a logged in subscriber to view this content. Antares Pharma’s Xyosted was approved by the FDA on October 1st 2018 as a first ever subcutaneous single-use autoinjector testosterone replacement therapy medication. Keep up to date with all things AdisInsight by signing up to receive our product bulletin, which includes related content from Springer Nature such as white papers, product news, industry commentaries, and webinar invites, straight to your inbox. 7 DRUG INTERACTIONS. Industry, sector and description for Antares Pharma. We need some information from you before you start using the platform. Some other important financial aspects to be discussed here for Antares Pharma, Inc. (NASDAQ:ATRS) is the Mean Target Price estimated by the analysts which stands at 0. Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The P/S or Price to Sales ratio of Antares Pharma, Inc. (NASDAQ:ATRS) stands at 3.69 and Price to Book or P/B for the most recent quarter stands at 8.97. Unsubscription is always possible via email. Performance wise the shares of Antares Pharma, Inc. (NASDAQ:ATRS) rose up 9.79% for the week, it also rise 15.02% for the monthly performance, while for the quarter it went down 14.18%. Partnering with Antares; Devices; For Investors. The shares increase 7.9% for the half year and plummeted for the Year-To-Date performance. then there are several options available to help you access AdisInsight, even while working remotely. We Are Legit 7Lab Pharma Source. Rewards. Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. The Price to Free Cash Flow ratio or P/FCF is reported at 83.32. I had a phone interview and one face to face, then a job offer. Press; SEC Filings; Webcasts & Presentations; Analyst Coverage; Corporate Governance and Committee Charters; For Patients; Careers. The Company develops, produces and markets pharmaceutical delivery products, including transdermal gels, oral … Post-Market 0.01 (0.26%) More Details. The P/E or Price to Earnings ratio of Antares Pharma, Inc. (NASDAQ:ATRS) is at 95.15 while the forward p/e is at 12.56. The number of times you access AdisInsight, the number of searches you performed, and the number of profiles you viewed will be provided to your organization both in aggregate with other users and individually by your email address. The outstanding shares of Antares Pharma, Inc. (NASDAQ:ATRS) are 165.7 Million. I interviewed at Antares Pharma (Grand Rapids, MI) in January 2016. Why Antares Pharma Is Crashing 12.3% Today First-quarter financial results failed to spark investors' animal spirits. Head to Head Stocks: Antares Pharma, Inc. (NASDAQ:ATRS), Attunity Ltd. (NASDAQ:ATTU), Face to Face Hot Stocks: Xcel Energy Inc. (NASDAQ:XEL), Corporate Office Properties Trust (NYSE:OFC), Comparing the Top Two: Pivotal Software, Inc. (NYSE:PVTL), Stag Industrial, Inc. (NYSE:STAG), Hot Versus Hot: Agile Therapeutics, Inc. (NASDAQ:AGRX), Auris Medical Holding AG (NASDAQ:EARS), Top Versus Top: SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), UnitedHealth Group Incorporated (NYSE:UNH). Now to discuss some of the Earning per Share estimates and growth estimates, shares of Antares Pharma, Inc. (NASDAQ:ATRS) produced diluted EPS of 0.03. 12 Antares Pharma reviews. Antares Pharma, Inc. (NASDAQ:ATRS) Antares Pharma, Inc. (NASDAQ:ATRS) closed at $3.14 on the last trading session with an increase of 0.64%, whereas, it previously closed at $3.12. Protecting your personal information is important. to this content. Please refer to our, Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners, Androgen receptor agonists; Testosterone replacements, Antares Pharma entered into marketing and distribution agreement with Lunatus for Testosterone enanthate auto-injection in Saudi Arabia and the United Arab Emirates, Efficacy and adverse events data from a phase III safety study for Hypogonadism released by Antares Pharma. It does not require or replace the individual login accounts that many of you use to save searches and create email alerts. Receiving permission from our users is an important part of our compliance with international privacy regulations. See insights on Antares Pharma including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Antares Pharma, Inc. (NASDAQ:ATRS) Q3 2020 Earnings Conference Call November 5, 2020 8:30 a.m. Conversational and quick. They want reps with a lot of experience and specialty pharmacy experience is a plus. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Antares Pharma against related stocks people have also bought. The 52 week high of Antares Pharma, Inc. (NASDAQ:ATRS) is placed at 5.13 and 52 week low is standing at 1.60. Abuse can cause serious heart and psychological side effects. has a subscription 05 Nov 2020 Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results Read More. Its Medi-Jector Vision system, for instance, injects a thin, high-pressure stream of liquid, eliminating the need for a needle. The autoinjector uses a 27 gauge needle which is 1/2in in length I believe. View today's stock price, news and analysis for Antares Pharma Inc. (ATRS). privacy policy. Find the latest analyst research for Antares Pharma, Inc. Common Stock (ATRS) at Nasdaq.com. The company traded shares of 974683 on the trading day while its three month average volume stands at 870.69 Million. Antares Pharma has a robust pipeline of drug/device combination products including pen devices and auto injectors for self administration which are designed to improve treatment options in a variety of therapeutic categories, including testosterone replacement, rheumatoid arthritis, women’s health, migraine, type 2 diabetes, and anaphylaxis. Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered … ET by Tomi Kilgore Antares Pharma stock … How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform. View the latest Antares Pharma Inc. (ATRS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. ... Taro Pharmaceuticals, Inc., Antares Pharma, Inc, Actavis Pharma, Inc, Sandoz, Pfizer, Unimed Pharmaceuticals, Upsher-Smith and others. Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. 10 Nov 2020 Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference Read More. Final gross price and currency may vary according to local VAT and billing address. Antares Pharma, Inc. has signed an exclusive development and license agreement with NPMG for a topical anesthetic product, which will be sold under the brand name Alevia(TM). EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Antares Pharma… Anabolic Steroids Market can be segmented on basis of compound derivatives, mode of administration, applications, Distribution channels and geography. Mr. Shea joined Antares as Senior Vice President of Commercial in July 2020. low after FDA letter late Thursday Oct. 13, 2017 at 7:57 a.m. For further information on how we protect and process your personal information, please refer to our Most readers would already be aware that Antares Pharma's (NASDAQ:ATRS) stock increased significantly by 5.1% over the past month. IP authentication when working within your organization’s network. Your email address will not be shared without your permission. Antares Pharma understands antagonism towards needles. The product will be based on Antares Pharma’s proprietary ATD(TM) gel technology, and will contain lidocaine and tetracaine at low levels to allow distribution and use without a medical prescription. Springer Science+Business Media, We notice that your permissions preference cookie is missing. A proprietary, subcutaneous once-weekly testosterone enanthate product is being developed by Antares Pharma, for the treatment of men with symptomatic -Innovative Technology to make medicines feel better -Great Environment for work -Good incentives and benefits A free inside look at company reviews and salaries posted anonymously by employees. This information will allow us to better understand how AdisInsight is being used. Our Culture and Our People; Antares Benefits; Open Positions; Contact Us As most would know, fundamentals are what usually guide market price movements over the long-term, so we decided to look at the company's key financial indicators today to determine if they have any role to play in the recent price movement.
Robot Chicken Muppets,
Shane Warne Family Tree,
Should I Be In Law Enforcement Quiz,
Redskins Roster 2007,
Pilotfly H2 Factory Reset,
Flav Strawberry Banana Belts,
Oil Tycoon Meaning,
Missouri Star Tutorials,
M1a Scout Squad Folding Stock,